EU4Monitoring Drugs (EU4MD) II

Making the link between drug-related problems and security and health threats in the European Union and neighbourhood countries 

EU4Monitoring Drugs (EU4MD) is an EMCDDA project to help countries neighbouring the European Union to monitor the drug problem. The EU-funded project aims to strengthen cooperation and share expertise with the countries in the European Neighbourhood Policy (ENP) area. The first phase of EU4MD ran from 2019 to 2022 (see timeline below). The second phase (EU4MD II) will run from 2023 to the end of 2027.


Milestones of the EU4Monitoring Drugs project 2019−2022

Partnerships Study Capacity building

The source data for this graphic is available on this page.

The EU4MD II project will:

  • seek to increase the technical expertise and capacity of the ENP partners to develop and contribute to contemporary drug monitoring and response systems;
  • work to increase the capacity to collect and exchange data in order to co-produce strategic analyses on emerging trends and threats in drug markets bordering the EU;
  • enhance the preparedness of ENP partners to respond to emerging drug-related health and security threats in the ENP region.

EU4MD II will have a stronger focus on the consolidation of the national monitoring systems. This will be achieved by providing structured support to national drug observatories, where they exist, or by supporting the national policymakers in their discussions on national drug monitoring systems.

Networking and partnership are central to EU4MD. The exchange of information and promising practices between ENP partners and EU Member States and experts on drug-related matters will remain a cornerstone of the cooperation.

The main activities of EU4MD II are:

  • the integration of the partners in the EU networks;
  • the integration with the European School Survey Project on Alcohol and Other Drugs (ESPAD) and Mediterranean School Survey Project on Alcohol and Other Drugs (MedSPAD);
  • drug residue analyses in used syringes;
  • monitoring of drug-related hospital emergencies;
  • assessment of the drug problem based on wastewater analysis;
  • exchange of information on new psychoactive substances;
  • collection and analysis of data on drug-related security threats;
  • collection and analysis of data on drug-related health responses;
  • scholarships to European Winter and Summer Drugs School;
  • training on a wide range of drug-related health and security topics.

The project budget is EUR 4 million.

Partner countries

  Map showing partner countries of the EU4MD project.

Algeria, Armenia, Azerbaijan, Belarus (suspended), Georgia, IsraelJordan, LebanonLibya, MoldovaMorocco, Palestine*, Tunisia, Ukraine


The involvement of other countries bordering the region is also possible. Participation in the project activities is on a case-by-case basis, within the context of EU4MD’s overall objectives.






*Palestine: This designation shall not be construed as recognition of a State of Palestine and is without prejudice to the individual positions of the Member States on this issue.